engineered coagulant protein has been promoted by many medical experts for expanded usage in the management of medical, surgical, and traumaassociated bleeding in hospitalized patients. There is no question that NovoSeven administration has been associated with numerous miraculous saves; however, there also is a dearth of well-controlled clinical trials that could provide insight into what criteria should be applied to maximize its safe use in the context of its known potential thrombogenicity.
More recently the Israeli and US armies have used NovoSeven for the control of bleeding occurring with battlefield and combat trauma. The US Army has developed and posted guidelines for the use of recombinant FVIIa in military hospitals. Although this use of NovoSeven is off-label and nonstandardized, the Army is to be commended for exploring its use in the management of bleeding in battlefield conditions where the conventional methods have not always been effective.
A recent article, "Dangerous Remedy. Military doctors in Iraq say that factor VIIa saves wounded soldiers, but other doctors and medical research suggest that it can cause fatal clots" (Baltimore Sun, November 19, 2006) authored by Robert Little, a Sun reporter, has provided a comprehensive review of the adverse thrombogenic complications associated with the use of NovoSeven. This article reported that the US Amy has injected more than 1000 trauma-inflicted soldiers with NovoSeven. The Baltimore Sun article is based on the extensive battlefield observations and research conducted by the reporter. Moreover, the reporter also interviewed several experts in the field of hemostasis and Recombinant activated factor VII (FVIIa; Novo-Seven, Novo Nordisk, Copenhagen) was approved by the United States (US) Food and Drug Administration (FDA) in March 1999 for the alternate hemostatic management of hemophilia patients who develop antibodies to FVIII. Although medically useful, there have been reports of adverse thrombogenic complications associated with its use. [1] [2] [3] In an article published in the Journal of the American Medical Association in December 2005, the FDA cautioned that the administration of NovoSeven for heretofore unlicensed indications to healthy, nonhemophilic individuals could result in complications such as stroke and myocardial infarction, possibly leading to death. Almost all of these clotting complications were detected in older individuals administered NovoSeven to reverse bleeding not related to hemophilia. Clotting complications rarely have occurred in the much younger individuals with hemophilia-related antibodies who have received NovoSeven to treat or prevent active bleeding.
Because anecdotal reports have provided the impression that life-threatening and overwhelming bleeding complications in desperate situations could be treated successfully and rapidly with NovoSeven administration, the use of this genetically thrombosis and sought their opinion about how to assess the risk-to-benefit ratio of the clinical situation before administering NovoSeven. The thrombogenic effect of recombinant FVIIa has been attributed to its upregulated ability to trigger the formation of blood clots at sites of bleeding by complexing with a substance called tissue factor, which is present at sites of injury. Army trauma surgeons and advisors on combat medical care have stated that recombinant FVIIa is one of the most useful new tools the Army has to control bleeding in combat situations.
These statements may be true, but the potential complications with the use of this drug should not be ignored. In fact, at military hospitals in Germany and in the United States, physicians have reported an increased prevalence of unexplained strokes, myocardial infarctions, and pulmonary emboli in soldiers evacuated from combat.
The Baltimore Sun article represents a comprehensive news item of great public and clinical impact that has initiated a major debate and rightful concerns on the off-label use of NovoSeven. Our soldiers are already in great danger, and the availability of a life-saving drug such as NovoSeven is welcome. It is, however, equally important to recognize and investigate the reported adverse reactions with its use to avoid additional risk to these Army personnel.
The posted guidelines in battlefield hospitals encourage the liberal use of recombinant FVIIa in bleeding patients, and the drug is injected routinely on the suspicion of bleeding, even before it occurs. There is no risk stratification. A review of the available information on the use of recombinant FVIIa in Army hospitals identified some items of concern:
• The doses of recombinant FVIIa used have been rather high and may be excessive. The drug is available in 1.2-, 2.4-, and 4.8-mg lyophilized FVIIa vials, which are reconstituted with sterile water to obtain a 1-mg/mL solution. The recommended dosage of the rFVIIa is 120 µg/kg IV bolus. Additional redosing is recommended at 20 minutes if hemorrhage continues. 4 Depending upon the weight of the recipient, 3 to 4 vials may be combined, representing a total amount of 7.2 to 9.6 mg of FVIIa to be injected as a bolus. A 1-mg/mL solution of recombinant FVIIa represents a potent procoagulant, which on contact with blood in the trauma patient activates coagulation beyond the intended hemostatic effect. Such a practice will also add to the thrombogenic complications associated with the use of this drug.
The above represents our concerns and is provided to underscore the important considerations that should be taken into account at all levels to optimize the safe use of NovoSeven in battlefield conditions. It is the intention of this editorial to bring these concerns to the attention of those involved in the control of bleeding in medical, surgical, and trauma patients, as addressing these concerns will be helpful in identifying adverse events and their potential management.
We thank the Baltimore Sun for publishing this timely and serious report, which requires immediate action on the part of all concerned parties. We also thank the US Army Medical Corps, which has objectively identified some of these issues and will be responsible in a stepwise resolution of some of the concerns in eventually providing our soldiers safer approaches to use newer drugs in combat medicine.
There is no question that the judicious use of recombinant FVIIa on the battlefield, and careful analysis of the benefits and risks associated with its use, will provide the proof of principle for the use of this procoagulant in civilian trauma and surgical bleeding scenarios. Such observations should also serve to stimulate the conduct of well-designed clinical trials to ascertain safety and efficacy data and to establish optimal treatment regimens.
A recent review of ongoing trials on factor VIIa in trauma related indications and other off-label indications in special population groups suggests a major interest in clinical and surgical community is interested in validating the use of this hemostatic agents. Such trial will be of major value in assessing the clinical potential of recombinant factor VIIa with particular reference to safety issues.
